Moderna executive sees $13B annual COVID vaccine market in U.S.
carmengabriela/iStock Editorial via Getty Images


The Chief Commercial Officer of Moderna (NASDAQ:MRNA) projected Thursday that the annual market for U.S. COVID vaccines could reach $5.2B-12.9B depending on the price of the shots and eligibility criteria.
Speaking at MRNAâs 2022 R&D Day, Arpa Garay noted that her forecast assumes a $64-100 price per vaccine dose.

The low end of the projection assumes only the high-risk Americans â some 82M â would be eligible to receive the booster shots. The high end of the forecast is based on all 258M U.S. adults becoming eligible, yet only half opting to get them.
According to Garay, the proportion of the high-risk population that would be eligible to receive the shots would be about 340M globally.
Read more on Modernaâs (MRNA) R&D Day highlights.